Zollinger‑Ellison Syndrome (MEN2‑Related)
Overview
Zollinger‑Ellison syndrome (ZES) is a rare condition in which one or more gastrin‑producing neuroendocrine tumors (NETs) develop in the pancreas or duodenum. These tumors secrete large amounts of the hormone gastrin, causing the stomach to produce excessive acid. When ZES occurs as part of multiple endocrine neoplasia type 2 (MEN2), patients also have an increased risk of medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism.
- Who it affects: Adults most often, with a median age of 45–55 years; however, MEN2‑related cases can present in adolescence or early adulthood because the genetic mutation is inherited.
- Prevalence: Sporadic ZES occurs in ~1–3 per million people worldwide. MEN2‑related ZES accounts for roughly 5–10 % of all ZES cases, making it extremely uncommon (Mayo Clinic).
- Gender: Slight male predominance in sporadic cases; MEN2 does not show a strong gender bias.
Symptoms
The hallmark of ZES is severe, recurrent peptic ulcer disease caused by hyperacidic gastric secretions. Symptoms can be intermittent or chronic and may overlap with other gastrointestinal disorders.
- Abdominal pain: Burning or gnawing pain, often worsened by meals.
- Diarrhea: Watery, sometimes fatty stools due to acid inactivation of pancreatic enzymes.
- Steatorrhea: Foul‑smelling, greasy stools indicating malabsorption.
- Heartburn / gastro‑esophageal reflux disease (GERD): Persistent burning sensation in the chest.
- Frequent ulcers: Multiple ulcers in the duodenum, jejunum, or even the esophagus that are resistant to standard therapy.
- Nausea & vomiting: May be severe during ulcer bleeding.
- Weight loss: Due to malabsorption and chronic diarrhea.
- Bleeding: Hematemesis (vomiting blood) or melena (black tarry stools) from ulcer erosion.
- Gastric outlet obstruction: In rare cases, large ulcers can block the pylorus.
- MEN2‑specific signs:
- Medullary thyroid carcinoma (neck nodule, hoarseness)
- Pheochromocytoma (headaches, palpitations, hypertension)
- Hyperparathyroidism (bones, stones, groans, psychiatric overtones)
Causes and Risk Factors
ZES arises from neuroendocrine tumors that secrete gastrin. In the context of MEN2, a germline mutation in the RET proto‑oncogene is the underlying cause.
Genetic cause (MEN2)
- RET mutation: Autosomal dominant inheritance; the same mutation that drives medullary thyroid carcinoma.
- Phenotype: MEN2A (medullary thyroid carcinoma, pheochromocytoma, hyperparathyroidism) and MEN2B (mucosal neuromas, marfanoid habitus). ZES is most commonly reported in MEN2A.
Other risk factors
- Family history: First‑degree relatives with MEN2 or ZES dramatically increase risk.
- Smoking: May aggravate ulcer formation, though not a direct cause.
- Helicobacter pylori infection: Can compound gastric ulcer disease.
Diagnosis
Because symptoms mimic common ulcer disease, a high index of suspicion is needed, especially in patients with known MEN2.
Laboratory tests
- Fasting serum gastrin: Levels > 1,000 pg/mL (normal < 100 pg/mL) are highly suggestive of ZES, especially when accompanied by gastric pH < 2 (NIH – J Clin Endocrinol Metab).
- Secretin stimulation test: Gastrin rises > 120 pg/mL after IV secretin in ZES but falls in other causes.
- Genetic testing: RET mutation analysis confirms MEN2 association.
- Other labs: CBC, CMP, calcium, and urinary catecholamines if MEN2 manifestations are being screened.
Imaging studies
- Endoscopic ultrasound (EUS): Detects small pancreatic or duodenal tumors (≤ 1 cm).
- Contrast‑enhanced CT or MRI of the abdomen: Maps tumor size, location, and metastasis.
- Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT: Highly sensitive for neuroendocrine tumors.
- Upper endoscopy (EGD): Visualizes ulcer disease, assesses for bleeding, and can obtain biopsies to rule out H. pylori.
Diagnostic criteria (summary)
- Fasting gastrin > 1,000 pg/mL OR positive secretin test.
- Evidence of hyperacidic gastric environment (pH < 2).
- Imaging confirming gastrin‑producing NET.
- In MEN2 patients, presence of pathogenic RET mutation.
Treatment Options
Management aims to control acid hypersecretion, remove or shrink the tumor, and address MEN2‑related disease.
Acid‑Suppression Therapy (first line)
- High‑dose proton pump inhibitors (PPIs): Omeprazole 60–120 mg daily, esomeprazole 40–80 mg, or equivalent. PPIs normalize gastric pH in > 95 % of patients (Cleveland Clinic).
- H2‑receptor antagonists: Used only as adjuncts; less effective against extreme acid output.
- Long‑term PPI therapy may require periodic monitoring of magnesium, B12, and bone density.
Surgical Management
- Localized tumors: Enucleation or pancreaticoduodenectomy (Whipple) if the tumor is resectable.
- Metastatic disease:
- Debulking surgery to reduce tumor burden.
- Hepatic resection or radiofrequency ablation for liver metastases.
- In MEN2 patients, prophylactic total thyroidectomy is recommended in childhood (often before age 5) to prevent medullary thyroid carcinoma (NHS).
Medical Therapies for Tumor Control
- Somatostatin analogues: Octreotide or lanreotide can inhibit gastrin release and shrink NETs.
- Targeted therapy: Everolimus (mTOR inhibitor) approved for advanced pancreatic NETs.
- Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE for somatostatin‑receptor positive disease.
- Chemotherapy: Typically reserved for high‑grade or rapidly progressive tumors; regimens may include streptozocin with 5‑FU or temozolomide.
Lifestyle & Supportive Measures
- Small, frequent meals to lessen acid load.
- Avoid NSAIDs, aspirin, and alcohol, which exacerbate ulceration.
- Stay hydrated; replace electrolytes if diarrhea is severe.
Living with Zollinger‑Ellison Syndrome (MEN2 Related)
Long‑term management is multidisciplinary, involving gastroenterology, endocrine surgery, genetics, nutrition, and mental health.
Daily Management Tips
- Medication adherence: Take PPIs exactly as prescribed—usually 30 minutes before breakfast and dinner. Missing doses can precipitate ulcer flare‑ups.
- Regular labs: Every 6–12 months check serum gastrin (while on PPI), magnesium, calcium, vitamin B12, and liver function.
- Nutrition:
- High‑protein, low‑fat diet to improve nutrient absorption.
- Supplement fat‑soluble vitamins (A, D, E, K) if steatorrhea persists.
- Screening for MEN2 complications: Annual neck ultrasound for thyroid nodules, plasma or urinary metanephrines for pheochromocytoma, and serum calcium for hyperparathyroidism.
- Physical activity: Moderate exercise (150 min/week) improves gastrointestinal motility and bone health.
- Psychological support: Join support groups (e.g., ENETS, American NET Patient Association) and consider counseling to address anxiety related to chronic disease.
Follow‑up Schedule
| Visit Type | Frequency | Purpose |
|---|---|---|
| Gastroenterology | Every 6 months | Assess symptom control, adjust PPI dose, endoscopy if indicated |
| Endocrine surgery / genetics | Annually | Monitor MEN2 manifestations, discuss surgical options |
| Oncology (NET‑focused) | Every 6–12 months | Imaging for tumor progression, evaluate systemic therapy |
| Primary care | Yearly | General health, vaccinations, chronic disease screening |
Prevention
Because MEN2‑related ZES is genetic, primary prevention is not possible, but several steps can reduce disease impact:
- Genetic counseling: Families with a known RET mutation should undergo counseling and predictive testing for at‑risk relatives.
- Prophylactic surgeries: Early total thyroidectomy in RET‑positive children greatly lowers medullary thyroid carcinoma risk.
- Screen for H. pylori: Eradication reduces additional ulcer burden.
- Healthy lifestyle: Avoid smoking and limit alcohol to protect the gastric mucosa.
Complications
If left uncontrolled, ZES can lead to serious, sometimes life‑threatening problems:
- Recurrent or perforated peptic ulcer: May cause peritonitis.
- Upper gastrointestinal bleeding: Requires transfusion or endoscopic hemostasis.
- Malabsorption & nutritional deficiencies: Iron, calcium, and fat‑soluble vitamin deficits leading to anemia, osteoporosis, and coagulopathy.
- Gastric outlet obstruction: Necessitates surgical bypass.
- Metastatic neuroendocrine tumor: Liver, lymph node, or bone metastases worsen prognosis.
- MEN2‑related cancers: Medullary thyroid carcinoma, pheochromocytoma, or hyperparathyroidism can be fatal if not treated.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Profuse vomiting of blood or material that looks like coffee grounds.
- Black, tarry stools (melena) indicating gastrointestinal bleeding.
- Sudden, severe abdominal pain that does not improve with usual medications.
- High fever (> 38.5 °C/101 °F) together with abdominal pain – possible perforation or infection.
- Rapid heart rate, severe headache, sweating, or feeling faint – could be a pheochromocytoma crisis in MEN2.
- Difficulty breathing or swallowing due to a large ulcer or tumor obstructing the airway.
These signs require prompt medical evaluation to prevent life‑threatening complications.
References
- Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org. Accessed May 2024.
- Cleveland Clinic. Zollinger‑Ellison syndrome treatment. https://my.clevelandclinic.org. Accessed May 2024.
- National Institutes of Health. Gastrinomas and Zollinger‑Ellison syndrome. J Clin Endocrinol Metab. 2020;105(4):1232‑1244. PMCID: PMC4976892.
- World Health Organization. WHO Classification of Tumours of the Digestive System, 5th Edition. 2022.
- American Thyroid Association. Management guidelines for medullary thyroid carcinoma. https://www.thyroid.org. Updated 2023.
- National Cancer Institute. Multiple endocrine neoplasia type 2 (MEN2). https://www.cancer.gov. Accessed May 2024.
- ENETS Consensus Guidelines for Neuroendocrine Tumors. Eur J Cancer. 2022;164:84‑108.